Kairos Ventures portfolio company Axial Biotherapeutics announced the appointment of Dr. Gregory T. Bates as Senior Vice President of...

Read more

We are pleased to announce that our portfolio company Provivi, Inc. closed on the first $21 million of a...

Read more

We are pleased to announce that Symbiotix Biotherapies, Inc. is the latest company to join the Kairos portfolio. Founded in...

Read more

We are delighted to announce that MixComm Inc. is the latest company to join the Kairos portfolio. MixComm Inc....

Read more

We're excited to share that our portfolio company, Axial Biotherapeutics, has been selected as one of FierceBiotech's Fierce 15...

Read more

We are delighted to announce that Chimera Bioengineering is the latest company to join the Kairos portfolio. Founded in...

Read more

We are pleased to announce that Transient Plasma Systems (TPS) is the latest company to join the Kairos portfolio....

Read more

Healthline recently published an article on the importance of implantable drugs, including Delpor’s implant devices. The first half of...

Read more

This month, Axial Biotherapeutics announced the appointment of leading experts in the Autism Spectrum Disorders (ASD) field to its...

Read more

We are proud to announce that Kairos Venture Partners II, L.P., our second fund, has made its second investment...

Read more